Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 13/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28368822 | 1.00 | CA1 (0.51) | CA1CA2NFKB1CA4PTGER1 | |
| SCHEMBL8417756 | 0.89 | BACE1 (0.48) | CA1CA2NFKB1CA4PTGER1 | |
| SCHEMBL8417755 | 0.89 | BACE1 (0.48) | CA1CA2NFKB1CA4PTGER1 | |
| SCHEMBL29085632 | 0.86 | PDCD1 (0.48) | PDCD1CD274 | |
| SCHEMBL181054 | 0.84 | PTGER3 (0.66) | CA1CA2NFKB1CA4PTGER1 | |
| SCHEMBL2433472 | 0.84 | PTGER3 (0.66) | CA1CA2NFKB1CA4PTGER1 | |
| Hydrochloric Acid SCHEMBL11527565 | 0.82 | PTGER3 (0.64) | CA1CA2NFKB1CA4PTGER1 | |
| SCHEMBL30671346 | 0.82 | PDCD1 (0.47) | CA1CA2PDCD1CD274MAPT | |
| SCHEMBL17802338 | 0.81 | CA1 (0.53) | CA1CA2NFKB1CA4PTGER1 | |
| SCHEMBL2303374 | 0.81 | CA1 (0.53) | CA1CA2NFKB1CA4PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | CA1 1327/4885CA2 790/4885NFKB1 2365/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | CA1 1327/4885CA2 790/4885NFKB1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.